AR066954A1 - Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR066954A1 AR066954A1 ARP080102477A ARP080102477A AR066954A1 AR 066954 A1 AR066954 A1 AR 066954A1 AR P080102477 A ARP080102477 A AR P080102477A AR P080102477 A ARP080102477 A AR P080102477A AR 066954 A1 AR066954 A1 AR 066954A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- groups
- alkyl
- optionally substituted
- chosen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Medicamento, composicion farmacéutica y uso para enfermedades donde esta implicada VEGFR-3 por ejemplo: cáncer, metástasis, artrosis psoriasis, inflamacion autoinmunes. Reivindicacion 1: Compuesto que responde a la formula (1) en la que: R1 y R2 (1) representan independientemente el uno del otro: bien un átomo de hidrogeno, bien un grupo alquilo C1-7, un grupo -CO-alquilo C1-7 o un grupo cicloalquilo C3-8, en los que dichos grupos alquilo y cicloalquilo están sustituidos opcionalmente con uno o varios grupos elegidos entre los átomos de halogeno y los grupos hidroxi y alcoxi, bien un grupo fenilo sustituido opcionalmente con uno o varios grupos elegidos entre los átomos de halogeno, los grupos alquilos C1-4, alcoxi C1-4, hidroxi, -OCF3, -CF3, -CN, -NRR', en los que R y R' son tales como se definen a continuacion, bien un grupo heteroarilo sustituido opcionalmente en cualquier posicion, comprendido un átomo de nitrogeno de dicho heteroarilo, con uno o varios grupos elegidos entre los átomos de halogeno, los grupos alquilos C1-4 y los grupos -NRR' en los que R y R' son tales como se definen a continuacion, (2) o R1 y R2 forman juntos, con el átomo de carbono al que están unidos: bien un grupo cicloalquilo C4-8; bien un grupo heterocíclico saturado de 4 a 8 eslabones que comprende un heteroátomo elegido entre los átomos N O y S, y pudiendo estar dicho grupo heterocíclico fusionado con un grupo fenilo; R3 representa: bien un grupo alquilo C1-7 lineal o ramificado o un grupo alquilo C3-7 en el que al menos 3 átomos de carbono están ciclados, estando dicho grupo alquilo sustituido opcionalmente con uno o varios grupos elegidos entre los átomos de halogeno y los grupos hidroxi, alcoxi, -NRR', -CF3 y -SO2-alquilo(C1-4), en los que R y R' son tales como se definen a continuacion; bien un grupo -(CH2)n-heterocíclico, en el que n = 0, 1, 2 o 3 y en el que el grupo heterocíclico comprende entre 4 y 8 eslabones y comprende al menos un heteroátomo elegido entre los átomos N, O y S, en el que dicho grupo heterocíclico está sustituido opcionalmente con un grupo oxo, bien un grupo -(CH2)n-heteroarilo, en el que n = 0, 1, 2 o 3 y en el que el grupo heteroarilo comprende 5 o 6 eslabones y comprende uno o varios heteroátomos elegidos entre nitrogeno, oxigeno y azufre; R4 representa un átomo de hidrogeno, un grupo alquilo C1-4 o un grupo alcoxi C1-4; R y R' representan independientemente el uno del otro un átomo de hidrogeno, un grupo alquilo C1-4 en el estado de base o de sal de adicion a un ácido, así como en el estado de hidrato o de solvato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0704192A FR2917412B1 (fr) | 2007-06-13 | 2007-06-13 | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066954A1 true AR066954A1 (es) | 2009-09-23 |
Family
ID=38870275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102477A AR066954A1 (es) | 2007-06-13 | 2008-06-11 | Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeutica |
Country Status (44)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2917413B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2952934B1 (fr) | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2954943B1 (fr) * | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| FR2965263A1 (fr) | 2010-09-24 | 2012-03-30 | Sanofi Aventis | Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| JP5748210B2 (ja) * | 2011-05-26 | 2015-07-15 | 日本化薬株式会社 | 複素環化合物の製造方法 |
| PT2874625T (pt) * | 2012-07-17 | 2017-08-16 | Sanofi Sa | Uso de inibidores vegfr-3 para tratar carcinoma hepatocelular |
| CN108558869B (zh) * | 2018-05-10 | 2019-04-09 | 西安培华学院 | 用于治疗肝癌的化合物及其制剂 |
| CN110981869A (zh) * | 2019-12-10 | 2020-04-10 | 天津科技大学 | 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用 |
| CN116509854B (zh) * | 2023-04-26 | 2025-05-23 | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 一种萘啶酮衍生物的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE258437T1 (de) * | 1995-08-02 | 2004-02-15 | Darwin Discovery Ltd | Chinolone und deren therapeutische verwendung |
| WO1999038867A1 (en) * | 1998-01-29 | 1999-08-05 | Suntory Limited | 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity |
| WO2002094823A1 (en) * | 2001-05-24 | 2002-11-28 | Merck Frosst Canada & Co. | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| JP2008501628A (ja) | 2004-06-02 | 2008-01-24 | 武田薬品工業株式会社 | インドール誘導体およびがんの治療用途 |
| FR2917413B1 (fr) * | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
-
2007
- 2007-06-13 FR FR0704192A patent/FR2917412B1/fr not_active Expired - Fee Related
-
2008
- 2008-05-27 PA PA20088781701A patent/PA8781701A1/es unknown
- 2008-06-11 SI SI200830273T patent/SI2158201T1/sl unknown
- 2008-06-11 JP JP2010511680A patent/JP5343072B2/ja active Active
- 2008-06-11 HR HR20110515T patent/HRP20110515T1/hr unknown
- 2008-06-11 AT AT08826268T patent/ATE505469T1/de active
- 2008-06-11 PT PT08826268T patent/PT2158201E/pt unknown
- 2008-06-11 CA CA2690337A patent/CA2690337C/fr active Active
- 2008-06-11 EP EP08826268A patent/EP2158201B1/fr active Active
- 2008-06-11 DE DE602008006188T patent/DE602008006188D1/de active Active
- 2008-06-11 NZ NZ581839A patent/NZ581839A/en not_active IP Right Cessation
- 2008-06-11 AR ARP080102477A patent/AR066954A1/es unknown
- 2008-06-11 MX MX2009013515A patent/MX2009013515A/es active IP Right Grant
- 2008-06-11 AP AP2010005099A patent/AP2590A/xx active
- 2008-06-11 AU AU2008274099A patent/AU2008274099B2/en active Active
- 2008-06-11 KR KR1020097025888A patent/KR101517636B1/ko not_active Expired - Fee Related
- 2008-06-11 EA EA201070009A patent/EA016939B1/ru not_active IP Right Cessation
- 2008-06-11 BR BRPI0814035-9A patent/BRPI0814035B1/pt active IP Right Grant
- 2008-06-11 MY MYPI20095271A patent/MY157754A/en unknown
- 2008-06-11 WO PCT/FR2008/000793 patent/WO2009007535A2/fr not_active Ceased
- 2008-06-11 DK DK08826268.8T patent/DK2158201T3/da active
- 2008-06-11 PE PE2008000997A patent/PE20090307A1/es not_active Application Discontinuation
- 2008-06-11 UA UAA201000231A patent/UA96994C2/ru unknown
- 2008-06-11 PL PL08826268T patent/PL2158201T3/pl unknown
- 2008-06-11 ES ES08826268T patent/ES2365073T3/es active Active
- 2008-06-11 CN CN200880020027XA patent/CN101679427B/zh active Active
- 2008-06-11 ME MEP-2009-346A patent/ME00961B/me unknown
- 2008-06-11 TW TW097121818A patent/TWI405762B/zh not_active IP Right Cessation
- 2008-06-12 JO JO2008277A patent/JO2682B1/en active
- 2008-06-13 CL CL2008001775A patent/CL2008001775A1/es unknown
- 2008-06-13 UY UY31152A patent/UY31152A1/es not_active Application Discontinuation
-
2009
- 2009-11-18 TN TNP2009000483A patent/TN2009000483A1/fr unknown
- 2009-11-25 DO DO2009000264A patent/DOP2009000264A/es unknown
- 2009-12-01 GT GT200900309A patent/GT200900309A/es unknown
- 2009-12-03 SV SV2009003429A patent/SV2009003429A/es not_active Application Discontinuation
- 2009-12-03 NI NI200900211A patent/NI200900211A/es unknown
- 2009-12-04 US US12/631,122 patent/US8470847B2/en active Active
- 2009-12-09 IL IL202640A patent/IL202640A/en not_active IP Right Cessation
- 2009-12-09 EC EC2009009791A patent/ECSP099791A/es unknown
- 2009-12-10 CR CR11157A patent/CR11157A/es unknown
- 2009-12-10 CO CO09141427A patent/CO6150150A2/es unknown
- 2009-12-11 HN HN2009003402A patent/HN2009003402A/es unknown
-
2010
- 2010-01-12 MA MA32508A patent/MA31567B1/fr unknown
-
2011
- 2011-06-16 CY CY20111100571T patent/CY1111631T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066954A1 (es) | Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeutica | |
| AR061994A1 (es) | Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden | |
| CO6251357A2 (es) | Nuevos derivados de acido azabifenilaminobenzoico | |
| AR064937A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica | |
| AR070207A1 (es) | Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica | |
| AR078833A1 (es) | Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3 | |
| AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| AR075332A1 (es) | Dionas ciclicas como herbicidas | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| CO6341575A2 (es) | Combinaciones que comprenden metotrexato e inhibidores de dhodh | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
| PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| AR075854A1 (es) | Inhibidores de beta- secretasa | |
| DOP2007000022A (es) | Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica | |
| PE20141193A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR070208A1 (es) | Derivados de carboxamidas n- azabiciclicas su preparacion y su aplicacion en terapeutica | |
| AR075892A1 (es) | Derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| PE20091811A1 (es) | DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1 | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |